CordSTEM-DD (Enhanced umbilical cord adherent stem cell therapy) / CHA Bio & Diostech - LARVOL DELTA

CHA Bio Group to showcase cell and gene tech at BIO 2024 in US (Korea Biomedical Review) - "CHA Bio Group said it would attend the 2024 BIO International Convention, the world's largest bio exhibition, from June 3 to 6 in San Diego, California...CHA Biotech will actively promote the development status of cell therapy drugs, including 'CBT101,' an anticancer immune cell therapy drug based on NK cells, and 'CordSTEM-DD,' a stem cell therapy drug. To maximize the effectiveness and characteristics of NK cell therapies, it is developing CAR-NK cell therapies that apply chimeric antigen receptor (CAR) and various combination therapies such as immuno-oncology drugs and antibodies, according to CHA Bio Group."

Clinical • CNS Disorders • Oncology • Solid Tumor

Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: CHABiotech CO., Ltd | Active, not recruiting ➔ Completed

Trial completion • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

CHA Biotech completes phase 1/2a clinical trial of 'CordSTEM-DD', a cell therapy for chronic back pain [Google translation] (Newspim) - "CHA Biotech announced on the 20th that it has successfully completed phase 1/2a clinical trials of 'CordSTEM-DD', a cell therapy for chronic back pain caused by degenerative lumbar intervertebral discs using umbilical cord-derived mesenchymal stem cells. In April 2022, the administration was completed to 30 subjects in the phase 1/2a clinical trial, and after a year of follow-up, a 'clinical trial completion report' was submitted to the Ministry of Food and Drug Safety....CHA Biotech plans to announce the results of phase 1/2a clinical trials within this year and submit an application for approval of the follow-up clinical trial plan to the Ministry of Food and Drug Safety."

P1/2 data • Trial status • Back Pain • CNS Disorders • Lumbar Back Pain • Pain

Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain (clinicaltrials.gov) - P1/2 | N=36 | Active, not recruiting | Sponsor: CHABiotech CO., Ltd | Not yet recruiting ➔ Active, not recruiting | Phase classification: P2 ➔ P1/2 | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Oct 2020 ➔ Apr 2023

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

CHA Biotech completes administration of chronic low back pain cell therapy phase 2a patients [Google translation] (Hankyung) - "CHA Biotech...announced...that it had finished administering to subjects in phase 2a clinical trial for 'CordSTEM-DD', a cell treatment for chronic low back pain caused by degenerative lumbar intervertebral discs. The company administered CordSTEM-DD to a total of 30 subjects, starting with the first patient in phase 2a in April last year. We plan to confirm the effectiveness with follow-up over the next one year. In the first half of next year, we plan to announce the main (top line) results of Phase 2a, and then apply for Phase 2b. After that, the company plans to apply for domestic product license and conduct technology export and overseas clinical trials at the same time."

New P2b trial • P2a data • Trial status • CNS Disorders • Lumbar Back Pain • Pain